HEALTH Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer Thursday, April 23, 2026 · epitopea Advertisement Read Original Article → Related Dispatches [US] · Jul 30 STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment [CA] · Jul 30 Family of N.S. mass shooting victim training educators on youth mental health, resilience [EU] · Jul 30 Questex’s Fierce Pharma announces launch of Fierce Pharma Week Europe in Basel, Switzerland in June 2027